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Abstract: 
Epitope prediction is becoming a key tool for vaccine discovery. Prospective analysis of bacterial and viral genomes can identify 
antigenic epitopes encoded within individual genes that may act as effective vaccines against specific pathogens. Since B-cell 
epitope prediction remains unreliable, we concentrate on T-cell epitopes, peptides which bind with high affinity to Major 
Histacompatibility Complexes (MHC). In this report, we evaluate the veracity of identified T-cell epitope ensembles, as generated 
by a cascade of predictive algorithms (SignalP, Vaxijen, MHCPred, IDEB, EpiJen), as a candidate vaccine against the model 
pathogen uropathogenic gram negative bacteria Escherichia coli (E-coli) strain 536 (O6:K15:H31). An immunoinformatic approach 
was used to identify 23 epitopes within the E-coli proteome. These epitopes constitute the most promiscuous antigenic sequences 
that bind across more than one HLA allele with high affinity (IC50 < 50nM). The reliability of software programmes used, 
polymorphic nature of genes encoding MHC and what this means for population coverage of this potential vaccine are discussed. 
 
 
 
Background: 
Human immunity comprises the innate and the adaptive 
immune response. Vaccination is principally concerned with 
humoral and cell mediated adaptive immune responses [1]. 
Vaccination generates effective and appropriate adaptive 
immune responses, to be activated subsequent to immunisation. 
The overall goal is the generation of long lasting immunity 
against microbial pathogens via the production of diverse 
immune memory cells. The Major Histacompatibility Complex 
(MHC) is a large region encoded on human chromosome 6; 
genes of the MHC are also known as Human Leukocyte 
Antigens (HLA), and demonstrate the highest levels of 
sequence polymorphism within the human population [2]. This 
genetic diversity is responsible for the adaptability of the 
human immune system to microorganisms and pathogens.  
 
T lymphocytes are integral to the adaptive, cell-mediated 
immune response against foreign substances, falling into two 
broad groups: T-cells (CD4) and cytotoxic T-cells (CD8), 
depending on the co-receptors they express. CD4 cells associate 
with Class I MHC and CD8 cells bind to class II MHC. In order 
for an effective immune response to occur, various threshold 
need to be surpassed [1]. Without effective processing of 
antigens by intracellular pathways and efficient presentation on 
the surface of Antigen Presenting Cells (APCs), then effective 
epitope-MHC-T-cell complexes cannot form. Effective T-Cell 
epitopes possess several key characteristics: the ability to be 
bound by MHCI and MHCII with high specificity and affinity; 
to form stable peptide-MHC complex that can bind with high 
affinity to T-cell receptors and subsequently activate T cells; 
antigenic peptides must be cleaved by the proteasome; for class 
I antigen presentation potential epitopes must be successfully 
transported by TAP; must be successfully secreted and 
presented on the cellular surface of Antigen Presenting Cells 
(APC); and to bind many MHCI and MHCII alleles with high 
affinity to provide wide population coverage. Epitopes which 
bind with high affinity to several MHC alleles tend to be 
stronger candidates for use within epitope-based vaccines. 
Currently, however, there is no real consensus as to what 
constitutes an optimal smallest set of ‘promiscuous’ epitope’s 
for inclusion in a vaccine. Within the context of reverse 
vaccinology, computer software enables rapid processing of 
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genomic data for vaccine discovery [1]. Gene sequences are 
identified as open reading frames, epitopes predicted within 
them, and filtered from several thousand epitopes to a few 
dozen candidate immunogens. Such immunogens then undergo 
experimental validation in vitro, in vivo, and in challenge 
models, before entering clinical trials. Current 
immunoinformatic software focuses on multi-step approaches 
for T-cell epitope identification, including: proteasome 
cleavage, TAP transport and MHC binding. These methods 
have the advantages of higher accuracy and a lower rate of false 
positive predictions, greatly reducing the number of peptides 
requiring testing.  
 
Computationally-driven genomic approaches to vaccine 
discovery remain challenging due to the high genetic diversity 
of pathogens. Gram-VE bacterium Escherichia coli are usually 
harmless, and are an important component of the gut 
microbiome; however, certain strains do cause disease and can 
be fatal. Specifically, uropathogenic Escherichia coli (UPEC) 
infection is a prevalent disease with potentially severe 
complications [3]. Globally, UPEC accounts for over 4 out of 5 
urinary tract infections. In the urinary tract, UPEC colonizes the 
bladder preferentially causing cystitis, and also infects the 
kidneys, causing pyelonephritis. Isolated initially from a patient 
with a urinary tract infection, the uropathogenic Escherichia 
coli strain 536 (O6:K15:H31), is now among the best-understood 
model pathogens; the availability of the O536 genome facilitates 
the computational identification of vaccine components. In this 
work, we describe the use of a novel immunoinformatic 
protocol to identify an optimal epitope ensemble as a putative 
candidate vaccine against uropathogenic E coli; we then explore 
the limitations of such strategies, highlighting the pressing need 
for experimental validation of this and other similar studies.  
 
Methodology: 
Rationale 
Promiscuous high-affinity epitope candidates suitable for 
inclusion in a vaccine were sought using a novel epitope 
prediction pipeline implemented using web-accessible 
prediction servers, as described below. Each step in the pipeline 
generates data requiring filtering. The process of re-scaling has 
its own problems [4]. A balance needs to be struck between 
conserving variability across epitope sequences and filtering 
out sub-optimal epitopes. Having a common measure 
describing the strength of epitope binding to MHC is important. 
It allows a direct comparison to be made between data obtained 
from different prediction servers.  
 
Pipeline Structure 
The structure of the pipeline is given in (Figure 1). SignalP [5] 
predicts which proteins from a virtual proteome files will be 
secreted via the Type II secretion pathway. Proteins predicted 
to be secreted by the SignalP server were filtered to isolate the 
top 5 scoring antigenic proteins using VaxiJen [6]. Class I and 
Class II peptide-MHC binding afinity for these proteins was 
then predicted using 3 reliable servers. MHCPred [7] (MHC 
Class 1 and 2) is an implementation of the additive method. 
CRB [8] predicts binding to 57 Human class I and 26 class II 
MHC alleles. IEDB [9] again predicts binding to a wide range of 
human MHC alleles. All three servers cover a wide range of 
human MHC alleles, all of which exist at high frequency in the 
global human population, and are based on a large collection of 
literature binding data. EpiJen predicts T-cell epitopes using a 
combination of proteasome cleavage, TAP transport, and MHC 
binding [10].  
 
 
Figure 1: Epitope Prediction Pipeline, Flowchart summarising 
the epitope prediction pipeline described in methods.  
 
Operation 
The pipeline described was in part run in serial mode (SignalP 
and VaxiJen) and in parallel mode (MHCPred, IEDB, and CRB). 
Epijen was run as a control, and its outputs compared to those 
generated by MHCPred, IEDB, and CRB. For all data harvested 
from web-servers, extensive off-line integration and filtering 
was used subsequent to data gathering. 
 
Exegesis  
Only proteins which are secreted or expressed on the cell 
surface proteins are accessible to immune surveillance, as 
identified here by SignalP, and are thus of interest. Only a 
subset of these, antigenic proteins as identified by VaxiJen, are 
likely to possess immunodominant epitopes. Such epitopes are, 
as predicted by MHCPred, IEDB, CRB, and EpiJen, those 
binding promiscuously at high affinity to many MHC alleles. 
From the final ranked lists of epitopes generated by MHCPred, 
IEDB, CRB, and EpiJen, a set of epitopes showing high affinity 
across servers and across multiple alleles was selected using a 
greedy breadth-first search protocol.  
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Discussion: 
We have described the identification of a multiple epitope 
ensemble as a candidate peptide vaccine. The virtual E coli 
proteome was assessed for potential epitopes using a pipeline 
composed of several servers: SignalP [5] (likelihood of protein 
secretion) followed by VaxiJen [6] (ranked antigenicity of 
secreted proteins) followed in parallel by MHCPred [7], IEDB 
[8], and NetMHC [9] (binding affinities of epitopes). EpiJen [10] 
was used as a control to assess the likelihood of epitope 
processing. The rationale for this pipeline is straightforward: 
only secreted proteins or those found on the cell surface, are 
accessible to immune surveillance, and of these, only a subset is 
likely to be antigenic, and are thus also likely to possess 
immunodominant epitopes [1]. The main problem in filtering 
strong epitopes from weak epitopes is defining a suitable 
threshold. A balance must be maintained between conserving 
successful epitopes and keeping the number of epitopes 
manageable for subsequent in vitro testing stage. Thus, only 
epitope sequences that occurred in two or more server outputs 
were used. This utilised the strategy implicit in all meta-servers 
that consensus prediction is inherently more robust and 
reliable. Only very high affinity epitopes with an IC50 value 
less than or equal to 50 were used. Epitopes also had to bind to 
more than one class I and class II allele.  
 
Using a breadth-first search strategy, the following 23 epitope 
sequences were identified as the smallest set of 
most promiscuous epitopes: ALAGVVPQY (active versus 
HLA0101, HLA0201); KLATLFLTA (HLA0101, HLA0201, 
HLA0203), MLSDAAPEV (HLA0201, HLA0202, HLA0203, 
HLA0206), SLISGSFLL (HLA0201, HLA0202, HLA0203, 
HLA0206), VMLNFKKTF (HLA0201, HLA1101), TLAAKDINV 
(HLA0202, HLA0203), LLSACIALA (HLA0202, HLA0203), 
ALSGDNNSV (HLA0202, HLA0203), NLNGGIQFV (HLA0202, 
HLA0203), TLSNSSSAV (HLA0202, HLA0203), FLSSSGGSA 
(HLA0202, HLA0203), ALITTLAIV (HLA0203, HLA0206), 
GIFAISALA (HLA0203, HLA1101, HLA6801), IVFSGSALA 
(HLA0203, HLA0206, HLA6801, HLA6802), FSLVTNEGI 
(HLA0203, HLADRB0701), FAISALAAT (HLA0206, HLA6801, 
HLADRB0101), AVLLLALLT (HLA0206, HLADRB0401), 
FNSLATMGV (HLA0206, HLADRB0701), KAVLLLALL 
(HLA6801, HLADRB0401), ISLAGSMKV (HLA6801, 
HLADRB0101, HLADRB0701), LSYVKSQRT (HLADRB0101, 
HLADRB0701), FNNSVSSMM (HLADRB0101, HLADRB0701), 
VQLVNSGTI (HLADRB0401, HLADRB0701).  
 
The current work shows strongly similarity to that of Wieser et 
al. [11] They identified computationally immunodominant 
epitopes from six virulence-associated E coli antigens: Usp, Iha, 
FyuA, ChuA, IreA, and IroN; creating two wholly artificial 
genes were created, each encoding eight extended peptide 
epitopes, which when expressed recombinantly resulted in a 
vaccine active against pathogenic but not benign E. coli in the 
gut. The important difference here was that this study, led by 
experimentalists, was validated experimentally [11].  
 
There are clear deficiencies in this and all other such studies. 
The poor predictivity of available software limits the ultimate 
reliability of all such studies. Servers facilitate vaccine 
development by assessing epitope binding affinity of different 
MHC alleles. Currently, the most reliable algorithms revolve 
around MHC I presentation with a heavy bias towards so-called 
HLA ‘supertypes’ [12]. There are 9 major supertypes showing 
commonality of peptide anchor binding specificity. Predictions 
for MHC class II binding by T cell epitopes, is by contrast poor 
and unreliable. Overall, the predictivity of software mirrors the 
degree to which particular HLA alleles have been studied. A 
strict consensus surrounding what a promiscuous epitope is 
and what features might make such an epitope suitable for 
inclusion in a vaccine remain largely undefined. If incorrectly 
defined it could lead to strong potential epitopes being missed 
out. The consequences including a longer development process 
with increased cost and enhanced chances of a poorly 
efficacious vaccine. Extending on the above discussion, size and 
variability of the immune response to pathogens and vaccines 
alike probably precludes the identification of very small sets of 
epitopes, as is common in published studies of this kind, since 
they will not evoke responses of sufficient strength and 
duration in a large enough section of the population to induce 
either immune memory or the necessary herd immunity 
essential for all effective vaccines.  
 
Likewise, failure properly to account for sequence similarity to 
other bacteria and to human proteome imposes severe 
constraints on the ultimate utility of any such study. We need to 
correct for any clear sequence similarity to other components of 
the gut microbiome, since vaccines also active against other, 
useful commensal bacteria would be of little utility. The 
problem here is that microbiome is large, complex, and variable 
on a local and global basis. Comparison with metagenomic 
analyses of the microbiome might prove the answer in this 
regard. Nor would it be good to induce autoimmunity against 
components of the human proteome that bare sequence 
similarity to an epitope ensemble. Unfortunately, proven and 
robust protocols able to identify such similarity are currently 
lacking.  
 
Conclusion: 
For all or nearly all in computational studies addressing real-
world problems, there is a pressing need for experimental 
validation. An increasing number of papers describing in silico 
analyses of genomes and proteomes, producing epitope 
ensembles as putative candidate vaccines, are now being 
published [13-19]. Most are sound, and, like the present study, 
even rigorous; yet their value cannot easily be quantified. As a 
consequence, their significance is questionable. Other studies 
[11, 20] by contrast combine immunoinformatic-driven vaccine 
design with experimental validation in various animal models, 
giving credence to their computational results. It has been said 
that theoreticians cannot “exist solely on morsels swept 
contemptuously from the experimentalists' table” [1], but 
equally prediction without validation will exert little influence 
and convince no one. Continuing to publish experimentally 
unverified papers is almost counterproductive in this context. 
Moreover, current research methodology is largely embodied in 
web-servers; operating such virtualised systems is facile, and 
the concomitant analysis of results straightforward. As the 
current paper amply demonstrates, the technical strictures 
inherent in the in silico design of epitope ensembles as candidate 
vaccines are quite within the ambit of undergraduate 
researchers. In sum, we can say that we have at once generated 
a sound prediction of an epitope ensemble vaccine and at the 
same time sought to highlight the severe limitations of all such 
studies in the absence of proper experimental validation.  
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